By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Helsinn Healthcare SA 

6912 Pazzallo-Lugano

Via Pian Scairolo    9  Switzerland
Phone: 41-91-985-21-21 Fax: +41-91-993-21-22


SEARCH JOBS

Helsinn is a privately owned cancer care pharmaceutical group with an extensive portfolio of marketed products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality, through a unique integrated licensing business model working with long standing partners in pharmaceuticals, medical devices and nutritional supplement products. Helsinn is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the US, a representative office in China, as well as a product presence in about 90 countries globally.

YEAR FOUNDED:

1976

JOBS:

Please click here for Helsinn job opportunities.

PRODUCTS:

All Products

FOLLOW HELSINN:




Key Statistics


Email: info@helsinn.com
Ownership: Private

Web Site: Helsinn
Employees:
Symbol: 
 



Industry
Healthcare






Company News
Helsinn And MEI Pharma (MEIP) Report Prolongation Of Survival Results From Phase 2 Clinical Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia 12/5/2016 6:43:05 AM
Helsinn And MEI Pharma (MEIP) Announce Long-Term Survival And Response Data From Phase II Clinical Study Of Pracinostat In Acute Myeloid Leukemia Accepted For Oral Presentation At Upcoming American Society of Hematology Annual Meeting 11/3/2016 7:52:17 AM
Helsinn Healthcare SA To Present At UBS Healthcare Conference In New York 5/23/2016 9:21:17 AM
Helsinn Healthcare SA,The University of Texas MD Anderson Cancer Center Enter Strategic Alliance To Improve Life Of Patients Conducting Clinical Studies In Cancer Supportive And Palliative Care 4/26/2016 6:43:19 AM
Helsinn Healthcare SA Reaches Settlement Agreement Regarding Patent Dispute On ALOXI 10/13/2015 6:48:10 AM
Zealand Pharma  (ZEAL.CO) And Helsinn Healthcare SA Announce The Advance Of Elsiglutide Into Phase IIB Development For The Prevention Of Chemotherapy-Induced Diarrhea 2/5/2015 7:50:17 AM
Helsinn Healthcare SA And Zealand Pharma  (ZEAL.CO) Announce The Advance Of Elsiglutide Into Phase 2B Development For The Prevention Of Chemotherapy-Induced Diarrhea 2/5/2015 7:20:15 AM
Helsinn Healthcare SA Reaches Settlement Agreement Regarding Patent Dispute On ALOXI® 1/12/2015 7:05:21 AM
Zealand Pharma and Helsinn Healthcare SA Announce Helsinn’s Decision to Advance the Development of Elsiglutide into Phase IIb for the Prevention of Chemotherapy-Induced Diarrhea 5/28/2013 9:09:30 AM
Zealand Pharma Receives Milestone Payment from Helsinn Healthcare SA 12/9/2010 11:24:11 AM
123
//-->